Veracyte Inc. (VCYT)
| Bid | 40.25 |
| Market Cap | 3.18B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.13 |
| PE Ratio (ttm) | -315.92 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 42.72 |
| Volume | 421,350 |
| Avg. Volume (20D) | 758,283 |
| Open | 41.97 |
| Previous Close | 42.11 |
| Day's Range | 40.44 - 42.21 |
| 52-Week Range | 18.61 - 47.32 |
| Beta | undefined |
About VCYT
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test ...
Analyst Forecast
According to 7 analyst ratings, the average rating for VCYT stock is "Buy." The 12-month stock price forecast is $42, which is an increase of 2.26% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago · businesswire.com
New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder CancerSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $VCYT--New Study Shows Veracyte's Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer.
